Literature DB >> 15469888

Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.

Toshiro Niwa1, Toyoko Hiroi, Daisuke Tsuzuki, Shigeo Yamamoto, Shizuo Narimatsu, Tsuyoshi Fukuda, Junichi Azuma, Yoshihiko Funae.   

Abstract

Metabolic activities toward endogenous substrates in the brain, progesterone and p-tyramine, by cytochrome P450 2D6.2 (CYP2D6.2), CYP2D6.10A, CYP2D6.10C, and P34S, G42R, R296C, and S486T mutants expressed in recombinant Saccharomyces cerevisiae were compared with those by CYP2D6.1 (wild-type) in order to clarify the effects of genetic polymorphism of CYP2D6 on the metabolism of neuroactive steroids and amines in the brain. For the 6beta-hydroxylation of progesterone, the V(max) values for CYP2D6.2, CYP2D6.10A, and the P34S and G42R mutants, were less than half of those for CYP2D6.1, and CYP2D6.10C had a higher K(m) and a lower V(max) than the wild-type. The V(max)/K(m) values for CYP2D6.10A, CYP2D6.10C, and the P34S and G42R mutants were 12-31% of that for CYP2D6. The 16alpha-hydroxylation and 21-hydroxylation of progesterone by CYP2D6.10A, CYP2D6.10C, and the P34S and G42R mutants were not detected, and the R296C mutant had a higher K(m) for the 16alpha-hydroxylation and a lower V(max) for the 21-hydroxylation than those for CYP2D6.1. For dopamine formation from p-tyramine, the K(m) values for CYP2D6.2 and the R296C mutant were higher than those for CYP2D6.1, CYP2D6.10A, and CYP2D6.10C had a higher K(m) and a lower V(max) than the wild-type. The V(max)/K(m) values for CYP2D6.2, CYP2D6.10A, CYP2D6.10C and the P34S, G42R and R296C mutants were less than 45% of those for the wild-type. These results suggest the possibility that the polymorphism of CYP2D6, including CYP2D6*2, CYP2D6*10 and CYP2D6*12, might affect an individual behavior and the central nervous system through endogenous compounds, such as neuroactive steroids and tyramine, in the brain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15469888     DOI: 10.1016/j.molbrainres.2004.06.030

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  12 in total

1.  Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6.

Authors:  Chitra Sridar; Natasha T Snider; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2011-02-02       Impact factor: 3.922

2.  Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2008-07-30       Impact factor: 7.853

Review 3.  The presence of endogenous morphine signaling in animals.

Authors:  George B Stefano; Patrick Cadet; Richard M Kream; Wei Zhu
Journal:  Neurochem Res       Date:  2008-09-06       Impact factor: 3.996

4.  Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.

Authors:  Amelia Nathania Dong; Nafees Ahemad; Yan Pan; Uma Devi Palanisamy; Beow Chin Yiap; Chin Eng Ong
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-04-26       Impact factor: 3.000

5.  3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.

Authors:  Yueying Zhen; Ondrej Slanar; Kristopher W Krausz; Chi Chen; Josef Slavík; Kerry L McPhail; T Mark Zabriskie; Frantisek Perlík; Frank J Gonzalez; Jeffrey R Idle
Journal:  Drug Metab Dispos       Date:  2006-06-16       Impact factor: 3.922

Review 6.  Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.

Authors:  Karla Claudio-Campos; Jorge Duconge; Carmen L Cadilla; Gualberto Ruaño
Journal:  Drug Metab Pers Ther       Date:  2015-06

7.  Inhibitory effects of phytochemicals on metabolic capabilities of CYP2D6(*)1 and CYP2D6(*)10 using cell-based models in vitro.

Authors:  Qiang Qu; Jian Qu; Lu Han; Min Zhan; Lan-xiang Wu; Yi-wen Zhang; Wei Zhang; Hong-hao Zhou
Journal:  Acta Pharmacol Sin       Date:  2014-05       Impact factor: 6.150

8.  Effect of Human Cytochrome P450 2D6 Polymorphism on Progesterone Hydroxylation.

Authors:  Toshiro Niwa; Shoko Sasaki; Yuka Yamamoto; Mayu Tanaka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-07-15       Impact factor: 2.569

Review 9.  Endogenous morphine/nitric oxide-coupled regulation of cellular physiology and gene expression: implications for cancer biology.

Authors:  George B Stefano; Richard M Kream; Kirk J Mantione; Melinda Sheehan; Patrick Cadet; Wei Zhu; Thomas V Bilfinger; Tobias Esch
Journal:  Semin Cancer Biol       Date:  2007-12-08       Impact factor: 15.707

10.  Human CYP2D6 in the Brain Is Protective Against Harmine-Induced Neurotoxicity: Evidence from Humanized CYP2D6 Transgenic Mice.

Authors:  Marlaina R Stocco; Cole Tolledo; Fariba Baghai Wadji; Frank J Gonzalez; Sharon Miksys; Rachel F Tyndale
Journal:  Mol Neurobiol       Date:  2020-08-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.